NeuroMetrix (NURO) Soars 30% Amid Receiving FDA Device Designation For Treatment of Fibromyalgia: Golden Opportunity

On Monday NeuroMetrix stock was at $3.08. Nevertheless, today the stock is skyrocketing amid positive news: it is currently at $4.07, resulting in a 32% gain. The company announced today that the Quell device has received Breakthrough Designation from the U.S. Food and Drug Administration to treat the symptoms of fibromyalgia in adults.

Fibromyalgia is a common form of chronic pain followed by fatigue, sleep, cognitive and mood disturbances. It affects an estimated 2-6 percent of the U.S. population (5-15 million people) and is diagnosed in people between 30 and 50. The cause of fibromyalgia remains unclear, but scientific studies explain abnormalities in the way the brain processes normal sensations, and pain is a key.

Quell is an advanced nerve stimulation device utilized by 18 U.S. utility patents. It is the only wearable neurostimulator that can be used by a custom-designed microchip that provides flexible, precise, high-power nerve stimulation in a form factor the size of a credit card. Quell uses position and motion sensing to automatically adjust stimulation for an optimal patient experience day and night.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.

Want Hot Stocks?    Yes. I Love Them No thanks